Essential Phospholipids in the Treatment of Nonalcoholic Fatty Liver Disease

Yu.М. Stepanov, Yu.A. Haidar, V.B. Yahmur, I.A. Klenina, D.V. Orlovskyi, I.S. Konenko, N.Yu. Oshmianska, L.O. Martynovа

Abstract


Nonalcoholic fatty liver disease (NAFLD) — a metabolic-related disease resulting from insulin resistance, which is characterized by fatty liver degeneration of varying degrees in the absence of other factors of liver injury. Insulin resistance leads to enhanced lipolysis of adipose tissue with excessive release of fatty acids and their accumulation in the liver. The clinical significance of NAFLD consists in the possibility of simple steatosis progression to liver cirrhosis. There was studied the influence of individual care containing preparation of essential phospholipids enerliv on cytolysis indicators, blood lipids and morphostructural changes of the liver in patients with NAFLD. Examination of patients after the treatment showed reduced activity of transaminases, increased blood content of phospholipids fraction and decreased atherogenic factor. According to the findings of control sonographic studies, a reduction in the size of the left lobe of the liver was observed.


Keywords


nonalcoholic fatty liver disease; insulin resistance; steatohepatitis; essential phospholipids

References


Papagianni M. Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease / M. Papagianni, A. Sofogianni, K. Tzio-malos // World J. Hepatol. — 2015. — № 8, 7(4). — P. 638-648.

Adams L.A. Non-alcoholic fatty liver disease / L.A. Adams, K.D. Lindor // Ann. Epidemiol. — 2007. — № 17(11). — P. 863-869.

Ekstedt M. Long-term follow-up of patients with NAFLD and elevated liver enzymes / M. Ekstedt, L.E. Franzen, U.L. Mathiesen, L. Thorelius [et al.] // Hepatol. — 2006. — № 44(4). — P. 865-873.

Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis / R.K. Semple, A. Sleigh, P.R. Murqatroyd, C.A. Adams // J. Clin. Invest. — 2009. — 119(2). — P. 315-322.

Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A Decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. P. Loria, L.E. Adinolfi, S. Bellentani [et al.] / NAFLD Expert Committee of the Associazione Italiana per lo studio del Fegato // Dig. Liver Dis. — 2010. — Vol. 42, № 4. — P. 272-82.

Serum Oxidative Stress Markers and Lipidomic Profile to Detect NASH Patients Responsive to an Antioxidant Treatment: A Pilot Study / P. Stiuso, I. Scognamiglio [et al.] // Oxidative Medicine and Cellular Longevity. — Vol. 2014. [Electronic Resource]. — Mode of access. — ID 169216, http://dx.doi.org/10.1155/2014/169216

Activity of essential phospholipids (EPL) from soybean in liver diseases / Karl-Josef Gundermann, Ann Kuenker // Pharmacological Reports. — 2011. — № 63. — P. 643-659.

Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial / C. Loguercio, P. Andreone, C. Brisc [et al.] // Free Radical Biology and Medicine. — 2012. — Vol. 52, № 9. — P. 1658-1665.

Єнюков І.С. Методи, алгоритми, програми багатомірного статистичного аналізу / І.С. Енюков // Фінанси і статистика. — 1986. — 86 с.




DOI: https://doi.org/10.22141/2308-2097.4.58.2015.81581

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru